Compound Glycyrrhizic Acid Monoammonium S for Injection

1 Anti-inflammatory effect (1) Anti-allergic effect: Glycyrrhizic acid glycoside can inhibit local allergic reactions in rabbits (Arthus Phenomenon) and inhibit Schwartsman phenomenon (Shwartsman Phenomenon) and other anti-allergic effects. For corticosteroids, it can enhance the hormone's inhibitory effect on stress response and antagonize the hormone's anti-granulation and thymic atrophy effects. It has no effect on the exudation of hormones. (2) Inhibition of arachidonic acid metabolic enzymes Glycyrrhizic acid glycoside can directly bind to phospholipase A2, the initiator enzyme of the arachidonic acid metabolic pathway, and act on arachidonic acid to produce inflammatory mediators.

This product is a compound preparation, its components are: glycyrrhizic acid, cysteine hydrochloride, and glycine.

Treat chronic liver disease and improve abnormal liver function. Can be used to treat eczema, dermatitis and urticaria.

Adults usually take 5-20 ml of the drug once a day by intravenous injection, which can be increased or decreased according to age and symptoms. Patients with chronic liver disease can take 40-60 ml of the drug once a day by intravenous injection or intravenous drip. The dosage can be increased or decreased according to age and symptoms, and the maximum dosage is 100 ml per day.

The results are from 789 cases in 15 foreign literatures on the same type of liver disease treatment and 4213 cases of the preparation approved by the Ministry of Health, Labor and Welfare of Japan for additional drug efficacy (improvement of liver function in chronic liver disease). In addition, the frequency of adverse reactions is unknown in the currently available information. 2. Important adverse reactions 1. Shock, anaphylactic shock (frequency unknown): Shock and anaphylactic shock (lowered blood pressure, unconsciousness, difficulty breathing, cardiopulmonary failure, flushing, facial edema, etc.) may sometimes occur, so pay full attention to observation. Once an abnormality occurs, the drug should be discontinued immediately and appropriate treatment should be given. 2. Allergic symptoms (Anaphylax

(The following patients should not be given this medicine) 1. Patients with a history of allergy to this product. 2. Patients with aldosteronism, myopathy, and hypokalemia (it may aggravate hypokalemia and hypertension).

Keep tightly closed in a cool, dark place.

Each bottle contains 40mg of monoammonium glycyrrhizinate S, 30mg of cysteine hydrochloride and 400mg of glycine.

Suzhou First Pharmacertical Co., Ltd.

• Founded in:

  2005-12-23

• Address:

  No. 1 Hualing Street, Suzhou Industrial Park

• Tax NO.:

  91320594783360722P

• Registered Funds:

  181.625 million yuan

• Email:

  Log in to view